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Attention-deficit and hyperactivity disorder (ADHD) often presents with 
comorbid substance use disorder (SUD). The extant literature on the comorbidity 
of adult ADHD and SUD was summarized on the etiology, prevalence, diagnosis, 
and treatment. ADHD is diagnosed in 15–20% of SUD patients, mostly as ADHD 
with a combined presentation. ADHD and SUD are believed to have shared patho-
physiology. ADHD is associated with the majority of dependence diagnoses. A 
most used screening questionnaire for screening ADHD patients presenting with 
SUD is the Adult ADHD Self-report Scale (ARSR). Evidence on pharmacological 
treatment is limited, but new trials support the use of long-acting stimulants as 
also recommended with a combination of psychotherapy by expert opinion. Given 
the prevalence of both ADHD and SUD, more research is needed to understand the 
theoretical and clinical implications of this comorbidity.
Keywords: adult, attention-deficit hyperactivity disorder, comorbidity, substance 
use disorders, clinical implications
1. Introduction
Attention-deficit and hyperactivity disorder (ADHD) is a neurodevelopmental 
disorder characterized by persistent symptoms of inattention and/or hyperactivity-
impulsivity. There are three subtypes of ADHD, marked by predominantly inat-
tentive symptoms, or by hyperactivity and impulsiveness, either a combination of 
inattentiveness and hyperactivity [1]. Studies suggest that the prevalence of ADHD 
among children may be as high as 15.5%, with approximately 20% of cases persist-
ing into adulthood [2, 3]. A lower prevalence of ADHD in adults compared with 
children is consistent with the age-dependent decline of the disorder, which has 
been confirmed in a meta-analysis [4]. ADHD is diagnosed twice as often in boys 
as in girls. Boys with ADHD tend to present with more impulsivity, while girls with 
ADHD tend to have more inattentiveness [5].
The etiology and pathophysiology of ADHD are incompletely understood. There 
is evidence of a genetic basis for ADHD and secondary environmental risk factors. 
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Differences in the dimensions of the frontal lobes, caudate nucleus, and cerebellar 
vermis have been demonstrated. Neuropsychological studies have demonstrated 
deficits in executive functioning and alterations in the motivation and reward 
among individuals with ADHD [6]. There is both empirical and theoretical sup-
port for an association between ADHD and SUD. ADHD and SUD are believed to 
have shared pathophysiology. Dopaminergic dysregulation of the motivational and 
reward system of the midbrain the basal ganglia and the frontal cortical regions 
influence executive functions and response inhibition which are key characteristics 
in both disorders [6, 7].
The essential feature of a substance use disorder (SUD) is a cluster of cognitive, 
behavioral, and physiological symptoms. This indicates that the individual contin-
ues using the substance despite significant substance-related problems. An essential 
characteristic of SUD is an underlying change in brain circuits. These changes may 
persist beyond detoxification, particularly in individuals with severe disorders. The 
behavioral effects of these brain changes may be exhibited in the repeated relapses 
and intense drug craving when the individuals are exposed to drug-related stimuli. 
The diagnosis of a SUD is based on a pathological pattern of behaviors related to use 
of the substance, which includes impaired control over substance use, the consum-
mation of substance in more significant amounts or over a longer period, persistent 
desire to cut down or regulate substance use, a great deal of time spent in using the 
substance, craving for the drug, social impairment, risky use of the substance, and 
pharmacological criteria including tolerance and withdrawal [1].
One of the most frequent co-occurring disorders with adult ADHD is SUD. A 
meta-analysis reported a prevalence of 15–20% of ADHD in adults diagnosed with 
SUD (nicotine excluded) [8, 9].
International consensus statement concluded that screening questionnaires 
such as the Adult ADHD Self-Report Scale (ASRS) are useful in screening patients 
presenting with SUD followed by in-depth diagnostic assessment if the screener is 
positive or if the clinician has a strong clinical feeling about the possible presence of 
ADHD. ADHD and SUD experts agreed that the simultaneous and integrated treat-
ment of ADHD and SUD using a combination of pharmaco- and psychotherapy is 
recommended [10].
The aim of this study is to summarize extant scientific literature concerning 
the comorbidity of ADHD and SUD on the etiology, prevalence, diagnosis, and 
treatment.
2. Methods
Publications on adults with combined ADHD and SUD were included focusing 
on etiology, prevalence, diagnosis and treatment. PubMed search was performed 
for articles published between 2010 and 2020 using the terms: adult ADHD, drug 
abuse, substance use disorder, addiction, and dependence. Publications were 
limited to articles published in English and were discarded if: they did not include 
adults; ADHD or SUD was not the primary diagnosis; they were reviews before a 
meta-analysis; they were personal opinion papers; and they were study protocols. 
The search was conducted on August 17, 2020.
3. Results
A total of 143 articles were found on initial search and screened on title and 
abstract. Of these, 68 articles did not discuss a combination of ADHD and SUD 
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specifically. Articles focusing solely on children or discussing other topics were 
excluded (n = 9) and also those in other languages (n = 7) or they were too old 
(n = 13). A total of 46 peer-reviewed studies were included for full-text review. 
Additional five articles were found with cross-referencing cited by authors that had 
not been found by initial research.
All together 51 articles were focusing either on etiology (n = 6), prevalence 
and symptom severity (n = 28), screening (n = 4), and treatment (n = 13) of adult 
ADHD and SUD.
3.1 Etiology
A study exploring childhood trauma exposure in SUD patient with ADHD and 
control group found higher rates of childhood trauma in ADHD and SUD patients, 
but not with the persistence of childhood ADHD into adulthood [11]. A familial 
risk analysis of probands followed from childhood to young adulthood found that 
SUDs in probands increased the risk for SUDs in relatives irrespective of ADHD 
status [12].
A large trans-ancestral genome-wide association study (GWAS) of alcohol 
dependence revealed common genetic underpinnings with ADHD, which indicates 
shared etiology between the two disorders [13]. Shared genetic susceptibility 
ADHD and SUD is also reported in Spanish study with polygenic scores based on 
GWAS [14]. Study on shared genetic contribution of the ADHD and SUD showed 
significantly increased frequency of the dopamine beta-hydroxylase (DBH) 
rs2519152 and the opioid receptor mu-1 (OPRM1) risk genotypes rs1799971 [15]. 
Dutch International Multicenter ADHD Genetics study reported that the serotonin 
genetic risk score significantly predicted alcohol use severity, but no significant 
serotonin × dopamine risk score or effect of stimulant medication was found [16]. 
An Italian study reported that patients with ADHD showed a higher intensity 
of craving for heroin than patients without ADHD in the absence of withdrawal 
symptoms. We can conclude on shared neurobiological mechanisms that mutually 
influence the evolution of both disorders where dopamine dysfunction within vari-
ous brain circuits may influence impulsivity levels, motivation, inhibitory control, 
executive functions, and behavior and, consequently, the intensity of craving [17].
A study which analyzed commercial health-care claims from adolescent and 
adult ADHD patients shows results that receiving ADHD medication is unlikely 
to be associated with a higher risk of substance-related problems in adolescence 
or adulthood. Instead, medication was associated with lower concurrent risk of 
substance-related events and, at least among men, with lower long-term risk of 
future substance-related events [18].
3.2 Prevalence and symptom severity
Existing evidence shows a prevalence of 15–20% of ADHD in adults diagnosed 
with SUD [8]. International European study exploring the prevalence of DSM-IV 
and DSM-5 adult ADHD varied from 5.4 to 32.6%. Prevalence estimates for DSM-5 
were slightly higher than for DSM-IV [19]. Another study on inpatients with 
alcohol dependence showed that ADHD prevalence was 20.5% [20]. Nigerian study 
observed an ADHD prevalence of 21.5% with the combined subtype being the most 
prevalent [21].
Adult ADHD was reported to be associated with fewer years of education, earlier 
initiation of regular tobacco use and more extensive lifetime poly-drug [22], as also 
with a more severe pattern of cocaine consumption [23]. ADHD in the cocaine-
dependent patient was associated with factors such as male gender, age at the start 
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of cocaine use and dependence, the amount of cocaine consumed weekly, increased 
occupational alteration, alcohol consumption, general psychological discomfort, 
depressive disorder, and antisocial personality disorder [24]. A large study reported 
that high rate of ADHD symptoms was found among heroin-dependent patients, 
particularly those affected by the most severe form of addiction. These individu-
als had higher rates of unemployment, other comorbid mental health conditions, 
and heavy tobacco smoking [25]. Another study reported that ADHD in long-term 
methadone maintenance treatment of patients is characterized by greater addiction 
severity and more comorbid psychopathology [26]. Mexican study reported that 
adolescents diagnosed with ADHD were more likely to have problems with use or 
abuse of or dependence on inhalants, and an elevated prevalence of parental SUDs 
was found in both the adolescent and adult groups [27].
Data from the National Epidemiologic Survey of Alcohol and Related Conditions 
(NESARC) on ADHD symptoms (DSM-IV) for the period when they were 
17 years old or younger showed that hyperactive-impulsive symptoms were more 
consistently associated with lifetime substance use and SUD compared to inatten-
tive symptoms [28]. Large American study investigated associations of lifetime 
hyperactive-impulsive ADHD and inattention ADHD. Both hyperactive-impulsive 
and inattention group were associated with the majority of dependence diagnoses in 
a linear pattern, such that each additional symptom was associated with a propor-
tional increase in odds of dependence. Both were uniquely associated with alcohol, 
nicotine, and polysubstance dependence, but only hyperactive-impulsive ADHD 
was uniquely associated with dependence on illicit substances [29].
Prospective outcome study reported that adults with childhood ADHD are 
more susceptible than peers to developing alcohol (adjusted OR 14.38, 95% CI 
1.49–138.88) and drug dependence (adjusted OR: 3.48, 95% CI: 1.38–8.79) [30]. 
A recent Dutch study confirmed this, where results showed that individuals with 
persistent ADHD were at significantly higher risk of development of SUD relative 
to healthy controls (OR = 4.56, CI 1.17–17.81). In contrast, levels of SUD in those 
with remittent ADHD were not different from healthy controls (OR = 1.00, CI: 
07–13.02). They concluded that SUD and nicotine dependence are associated with a 
negative ADHD outcome [31]. Similar results were reported in Italian study where 
patients with ADHD symptoms and high-dose benzodiazepine dependence showed 
a significantly larger prevalence of poly-drug abuse than ones without them [32].
A French study reported that a history of ADHD was associated with an earlier 
onset of addiction, poly-dependence, and borderline personality disorder [33]. An 
Australian study reported that conduct disorder, rather than ADHD, is the strongest 
predictor of differences in patterns of drug use severity. The extensive comorbid-
ity of those two highlights the great potential for misattributing drug use risks 
to ADHD [34]. A Dutch study on opioid-dependent patients found that conduct 
disorder patients had significantly higher problem severity scores, more frequent 
comorbid SUD, and more severe psychiatric comorbidity. ADHD was found to 
increase the risk of psychiatric comorbidity [35]. Another study on British prison-
ers, on the contrary, show that combined ADHD type is significantly associated 
with the need for coping as a way of managing primary and comorbid symptoms, 
but not conduct disorder [36]. Brazilian study also found no difference in drug use 
or dependence prevalence between ADHD and non-ADHD patients but observed 
different addiction patterns such as earlier use of cocaine and more severe use of 
cocaine correlated to earlier contact with cannabis [37]. The longitudinal study fol-
lowed participants with childhood-limited ADHD and persistent ADHD compared 
to controls and found that there were no significant group differences in change 
in rates of substance dependence over time. However, individuals whose ADHD 
persisted into adulthood were significantly more likely to meet DSM-IV criteria for 
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alcohol, marijuana, and nicotine dependence [38]. An Australian study conducted 
in drug and alcohol treatment centers reported increased drug dependence com-
plexity and chronicity in treatment-seeking SUD patients who screen positively for 
ADHD, specifically for amphetamine, alcohol, opiates other than heroin or metha-
done, and benzodiazepines [39].
A recent large study reported that symptoms of hyperactivity/restlessness and 
problems with self-concept increased the odds of having a diagnosis of ADHD and 
that impulsivity mediated the relationship between adult ADHD symptoms  
and alcohol dependence severity [40]. A Dutch study showed higher levels of motor 
and cognitive impulsivity in ADHD patients with comorbid cocaine dependence 
compared to ADHD patients without cocaine dependence and controls [41]. Belgian 
study also reported higher impulsivity in cocaine-dependent individuals to con-
trols, regardless of whether they have concomitant ADHD or not [42]. Similar was 
reported by Brazilian study where patients who had ADHD and cocaine dependence 
had impairments in both cognitive and affective regulation [43]. Another study on 
cocaine dependence reported that the Barkley’s executive dysfunction items showed 
statistically significant differences between cocaine-dependent patients with 
ADHD and those patients without ADHD diagnosis [44].
Swiss study reported that patients with probable adult ADHD showed higher 
craving, more withdrawal and psychiatric symptoms, and rated withdrawal symp-
toms as more severe than did patients without ADHD symptoms [45]. Hungary 
study of drug-dependent patients with and without ADHD symptoms reported 
the highest severity of aggression when the ADHD positive status co-occurred 
with heroin use, while the lowest severity of aggression was detected when ADHD 
negative status co-occurred with the use of marijuana. ADHD positive patients 
showed a marked increase in depression symptoms, suicidal ideation, suicidal 
attempts, as well as self-injuries associated with suicidal attempts [46]. Study on 
Scottish prisoners reported that ADHD symptoms were the strongest predictor, 
followed by alcohol dependence for violent offending. Hence, the authors pointed 
out the importance to treat drug addiction and ADHD symptoms in order to reduce 
offending among the most persistent offenders [47]. Taiwan study among heroin-
dependent participants entering methadone maintenance treatment showed that 
ADHD-screened positive patients showed higher depression scores (p = .003), and 
more severe heroin dependence (p = .006) [48]. Childhood ADHD was associated 
with obsessive-compulsive disorder, and both conditions were highly prevalent 
among former heroin addicts on methadone maintenance treatment [49].
3.3 Screening and diagnosis of ADHD and SUD
ADHD is a common comorbid disorder that is frequently overlooked in adults 
with SUD. DIVA diagnostic interview is important tool to diagnose ADHD in 
adult patients. Since it is an interview, it has greater diagnostic power then screen-
ing questioners. DIVA-5 is the successor to DIVA 2.0, the structured Diagnostic 
Interview for Adult ADHD, and is based on the criteria for ADHD in DSM-5 [50]. 
A most used screening questionnaire for screening ADHD patients presenting with 
SUD is the ASRS followed by in-depth diagnostic assessment [10]. In a Norwegian 
study, 33% of patients on opioid maintenance therapy [51] and in the Italian study, 
19.4% [25] were positive for ADHD using the ASRS. Among patients with benzodi-
azepine dependence, 32% of them screened positive on ADHD [32].
Brazilian study validated the translated version of the adult self-report The 
Brown Attention-Deficit Disorder Scale (BADDS) using the ASRS as the gold stan-
dard [52], but ASRS appears to be more appropriate screener that BADDS in SUD 
patients [53]. Conners’ Adult ADHD Diagnostic Interview for DSM-IV (CAADID) 
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proved to be a diagnostic tool that can also be used during active substance use [54]. 
Study investigating the clinical utility of two self-report screening instruments 
such as Conners’ Adult ADHD Rating Scale screening Self-Rating (CAARS-S-SR) 
and the ASRS in alcohol use disorder showed many false-negative results (ASRS: 
89.5%; CAARS-S-SR: 92.3%) which indicates underreporting of ADHD symptoms. 
Authors suggested that underreporting of ADHD symptoms in ASRS and CAARS-
S-SR of alcohol use disorder patients requires lower cut-off values to detect the 
majority of ADHD [55].
In a recent study from international multi-center, the Mini-International 
Neuropsychiatric Interview (MINI-Plus) on patients with substance use disorders 
was validated for the screening of adult ADHD in treatment-seeking SUD patients 
[56]. Another tool in understanding the possible causes and motivations behind 
substance misuse and its dependency is Substance Transitions in Addiction Rating 
Scale (STARS) where the subscales produced meaningful and reliable factors that 
supported the self-medication and behavioral disinhibition hypotheses of substance 
use motivation [36].
3.4 Treatment
Comorbid ADHD and SUD represent a challenge for health-care providers as 
the pharmacological trials have found mix results for efficacy [8]. The reviews on 
ADHD medications for ADHD with SUD point out limited efficacy of treatment, 
but more recent trials using psychostimulants in robust dosing have demonstrated 
positive results [57–60].
Guidelines recommend that when ADHD coexists with other psychopatholo-
gies in adults, the most impairing condition should generally be treated first [58]. 
Another approach is to first achieve abstinence before treating ADHD, where the 
main goal is to reduce the risk of diversion of stimulant medication [57]. The inter-
national consensus statement recommends long-acting stimulant medication [10].
While previous concerns arose whether stimulant therapy would increase the 
ultimate risk for substance abuse, recent studies have indicated that pharmacologic 
treatment appears to reduce the risk of substance abuse in individuals with ADHD 
[61]. Findings from 19 large open studies and controlled clinical trials show that the 
use of atomoxetine or extended-release methylphenidate formulations, together 
with psychological therapy, yield promising though inconclusive results about 
short-term efficacy of these drugs in the treatment of adult ADHD in patients with 
SUD and no other severe mental disorders. However, the efficacy of these drugs 
is scant or lacking in treating concurrent SUD [62]. The concern is as indicated by 
American study that ADHD is prevalent among chronic methamphetamine users, 
who are at increased risk for persistence of childhood diagnoses of ADHD into their 
adult years. ADHD also appears to play an important role in methamphetamine-
associated disability, indicating that targeted ADHD screening and treatment may 
help to improve real-world outcomes for individuals with methamphetamine use 
disorders [63].
A meta-analysis on the efficacy of atomoxetine in treating adult ADHD showed 
atomoxetine is efficacious in treating adult ADHD compared to placebo, though 
the efficacy is significantly superior for inattention than hyperactivity/impulsivity 
[64]. Study on alcohol-dependent patients with and without a diagnosis of ADHD 
hypothesized that atomoxetine could reduce the impulsivity trait [65]. A small 
study reported that atomoxetine may improve some ADHD symptoms but does not 
reduce marijuana use in marijuana-dependent adults with ADHD [66].
A small study on ADHD patient with cocaine use disorder showed that 
behaviors reflecting cocaine addiction were sharply reduced during the stimulant 
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treatment of adult ADHD, and were not correlated with age, gender, familiarity, 
length of treatment, or medication used. Cocaine use disorder improvement was 
closely correlated with adult ADHD improvement [67]. Earlier data show that 
patients with ADHD and comorbid cocaine dependence do not benefit signifi-
cantly from treatment with methylphenidate, where Dutch study showed that low 
dopamine transporter occupancy is not the reason for that. Authors also suggest 
that higher dosages of methylphenidate in these patients are probably not the 
solution and that medications directed at other pharmacological targets should be 
considered in these comorbid ADHD patients [68]. ADHD patients with cocaine 
dependence are a distinctly more impulsive subpopulation compared to ADHD 
patients without cocaine dependence on objective measures of impulsivity. These 
findings are relevant for optimizing psycho-education and treatment of ADHD 
patients with comorbid SUD [41].
Sweden placebo-controlled double-blind study reported that methylphenidate 
treatment reduces ADHD symptoms and the risk for relapse to substance use in 
criminal offenders with ADHD and substance dependence [69]. Norway study 
reported about the safety and utility of central stimulant medications for patients 
with ADHD who are receiving opioid maintenance treatment [70]. Sustained-
release methylphenidate in a double-blind, placebo-controlled trial for the treat-
ment of ADHD in amphetamine abusers found no difference with regards to the 
craving for amphetamine or in retention in treatment [71]. Another double-blind, 
placebo-controlled study in adults with ADHD reported that extended-release 
methylphenidate was statistically superior to placebo in reducing emotional 
symptoms and a decline of obsessive-compulsive symptoms and those of problems 
with self-concept. Symptoms of anxiety, depression, anger and hostility, phobia, 
paranoid ideations and psychoticism were not improved [72]. A study that exam-
ined if stimulants would decrease marijuana use in a randomized controlled trial 
of extended-release mixed amphetamine salts for the treatment of co-occurring 
ADHD and cocaine use disorders found no significant baseline differences in 
marijuana use frequency and quantity [73].
A recent Dutch randomized clinical trial among SUD and ADHD patients 
reported that integrated cognitive behavioral therapy resulted in a significant 
improvement in ADHD symptoms in comorbid SUD and ADHD patients [74]. This 
finding leads to the conclusion that nonpharmacological interventions can contribute 
to ADHD symptom reduction in patients with comorbid ADHD and SUD. ADHD 
and SUD experts recommend that simultaneous and integrated treatment of ADHD 
and SUD, using a combination of pharmaco- and psychotherapy, is effective [10].
4. Conclusions
ADHD is highly comorbid with SUD, being diagnosed up to 20% in SUD 
patients. ADHD and SUD are believed to have shared pathophysiology. ADHD 
is associated with the majority of dependence diagnoses. A most used screening 
questionnaire for screening ADHD patients presenting with SUD is the ASRS. 
Evidence on pharmacological treatment is limited, but new trials support the use of 
a higher dose of long-acting stimulants as also recommended with a combination of 
psychotherapy by expert opinion. Finally, the decision to treat adult ADHD in the 
context of SUD depends on various factors, so clinical decisions should be indi-
vidualized and based on a careful analysis of the advantages and disadvantages of 
pharmacological treatment for ADHD in the context of SUD. Given the prevalence 
of both ADHD and SUD, more research is needed to understand the theoretical and 
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